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Abstract 
The treatment of Adolescent and Young Adult Oncology patients requires a comprehensive 
understanding of the psychological and social complexity of this group. Psychosocial support is 
often coupled with clinical treatment, but there are still unmet needs within this population 
regarding relevant information, mental health counseling, practical resources, and others. A 
significant gap in available clinical trials and participation in clinical trials has prevented 
progress in clinical treatment of Adolescent and Young Adults with cancer. A review of 
pertinent literature on psychosocial needs and oncology clinical trials was conducted in order to 
examine any relationship between unmet needs and clinical trial participation. Adolescent and 
Young Adults with cancer who have symptoms of unmet psychosocial needs experience a lower 
participation rate of clinical trials. This suggests that an increase in available psychosocial 
resources and delivery of these resources to patients will increase clinical trial participation, 
furthering the clinical treatment capabilities of Adolescent and Young Adult Oncologists and 
increasing survival rates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cancer is one of the leading causes of death in both developed and underdeveloped 
countries and receives a substantial amount of attention and effort from the medical field. In 
oncology, the medical study of cancer, these advances have increased survivorship of pediatric 
patients aged one to fourteen from 28% to nearly 80% over the past 40 years.1 The following 
population of adolescents and young adults (AYAs) between the ages of 15 and 39, however, 
have not benefited from medical advancements to the extent of older and younger populations; 
five year survival rates of AYAs diagnosed with cancer have increased minimally between 1975 
and 1997, despite having 8 times the incidence of cancer than the pediatric population.2 Due to 
the gap in survival rates between these populations, a new subspecialty in oncology has emerged: 
Adolescent and Young Adult Oncology (AYAO). Specialists in this field are conducting 
research that addresses the unique and markedly heterogeneous psychosocial needs of the 
population, and the duration and quality of life of AYA cancer patients via biological 
understanding.2,3,4 In this analysis, I will examine the relevant literature and address the 
following question: How can AYA providers use information on the psychosocial needs of 
AYAs to increase survival rates for the population? By addressing the unmet psychosocial needs 
of the population, oncologists will be able to increase adherence rates, participation in clinical 
trials, and quality of life both during and after treatment. 
BIOLOGY 
One distinct challenge in treating AYA cancer patients is that the biology of disease is 
different in AYAs than in other age groups.5–8 The array of cancers that affect AYAs are not 
similar to any other age range and do not respond to treatment in the same manner as pediatric or 
adult cancer patients.5  More research must be conducted to better understand the etiology of 
cancers in AYAs. There are several barriers in advancing AYAO biology including a deficit of 
tumor banks, lack of a standardized care model, and difficulty tracing environmental carcinogens 
and family history of an AYA cancer patient.2,6,7 Most important is the lack of clinical trials 
available and utilized to study the biology of AYA cancers.1-3,9–11  
Significant evidence demonstrating the biological benefits of age specific clinical trials is 
seen in the increased use of randomized clinical trials in childhood Rhabdomyosarcoma (RMS).1 
Survival rates for the pediatric age group with high clinical trial participation have improved 
substantially over the past 25 years. Adult populations have not had clinical trials available to 
them and survival rates for RMS in adults have decreased.1 Other sarcomas such as non- 
Rhabdomyosarcoma soft-tissue sarcomas (NRSTSs) have received little to no study through 
clinical trial and none stratified for age. As a result, little is known about the treatment of these 
tumors and limited knowledge of their biological functioning in all age groups.1 
This same phenomenon is seen with the AYA age range of most cancers. Several oncologists 
have written articles dictating the importance of tissue sample collection and banking in order to 
make research on the biology of AYA cancers more viable.2,6,7 Specimen banks are particularly 
beneficial because research is conducted without the added complication of patient participation. 
Without a broad sample collection of both malignant and benign AYA tissues, research is 
significantly limited and contained within institutions. Most cancers in young adults are 
spontaneous carcinogenic mutations. There is a less conspicuous relationship to environmental 
carcinogens or family history making it more difficult to predict incidence or response to 
treatment.11 By increasing AYA tissues in tumor banks, researchers will have access to an array 
of samples and can conduct research independently of one another. 
The distinct lack of clinical trials available for AYA patients paired with the minimal 
participation of AYAs in clinical trials is one of the most common topics in the field. The low 
number of available trials for this age group stems in part from the use of strict age ranges due to 
pediatric protocols.3 In recognition of this, the upper age limit for pediatric group protocols has 
been increased to 30 or 40 years and new adult pediatric cooperative group trials have been 
established for research in several cancers, a marked success of collaboration efforts thus far.3 
However, the participation of AYA cancer patients in clinical trials remains a distinct barrier in 
learning about the unique pathology of their cancer. There are several practical and personal 
reasons that AYAs do not enroll in clinical trials: diagnosing physicians do not refer patients to 
current trials; high unemployment of this population results in limited funding for health care and 
often no insurance coverage to cover cost of treatment; the highly transient nature of this age 
range limits the number of participants who successfully commit to the duration of the trial; and 
the emotional distress experienced by AYAs fosters an indignant attitude toward any association 
with their diagnosis.1,2,3,9,11,12 Identified as unique challenges to the AYA population, these needs 
are being addressed by both psychosocial and clinical professionals. 
PSYCHOSOCIAL 
Several distinguishing social, developmental, biological, and psychological trends in 
AYAs have prompted scholars from many fields to research discrepancies for this population. 
Even before their cancer diagnosis, AYAs are at a disadvantage. This age range is associated 
with perceived invulnerability; few cancer prevention measures are targeted at this population 
and there is a distinct delay in accessing a physician for a medical concern.2 Once the AYA sees 
a primary care physician, their symptoms are often attributed to fatigue or stress and no further 
testing is conducted.2 If the patient is successfully diagnosed, there is no standardized referral 
pattern or treatment regimen for cancers in this age range; the patient may be referred to a 
pediatric oncologist, gynecological oncologist, or radiation oncologist who then decide how to 
treat the patient.2 A call for more structure in how to clinically treat AYAs is unanimous in all 
related disciplines. 
Relative to older and younger populations, AYA adherence rates are lower both in cancer 
and other chronic illnesses.12 Definitions of adherence vary between fields. Formerly described 
as compliance, the term adherence in nursing is seen as an active responsible role taken by the 
patient in the interest of their care.13 Other medical fields consider adherence to be valued strictly 
by compliance with medical advice such that non-compliance is the tardiness or absence of 
treatment when prescribed.13 In this analysis, adherence to medical advice will be used as the 
working definition. Adherence to treatment is often disrupted due to the same barriers of 
enrolling in clinical trials and significantly impacts the quality of life the patient experiences in 
survivorship.14 Non-adherence is of particular concern for cancer patients because it greatly 
decreases the efficiency of treatment and chance of survival.12 Limited communication between 
the patient, their oncology team, and their primary care physician both during and after treatment 
results in lessened adherence to follow-up testing and care, in addition to increased incidence of 
relapse.12,15  
More recent literature has eluded to a relationship between the unmet psychosocial needs 
of this population to their adherence to treatment and follow-up care.13,14 Psychosocial needs that 
have been identified by AYAs include: credible, relevant information specific to this age range 
available online; mental health services; socializing opportunities with other AYAs; and practical 
services such as transportation and childcare.14,16,17 Addressing these needs is the focus of social 
workers, psychologists, and oncologists alike. By increasing available resources to meet these 
needs, both quality of care and quality of life will be augmented for AYAs with cancer. 
Adolescents and young adults are all at unique milestones in their maturation and 
psychological development. At a time of life that is meant to be for exploration, experimentation, 
and self-discovery, a cancer diagnosis is devastating. Exploration is replaced with confinement 
and fatigue, experimentation is replaced with adherence, and self-discovery takes place in an 
environment of anxiety, fear, and various treatments. AYAs often experience severe emotional 
and physical distress after their diagnosis as well as in survivorship.16–18 Not only are their lives 
disrupted at one of the most critical stages in identity development, but their survival rates are 
lower than average due to stigma surrounding health status in this age group. This population is 
at the crux of medical and psychosocial disadvantage, and increasing awareness is not enough. 
More research and evaluation is necessary to improve the quality of life and survival rates for 
this population.  
LITERATURE REVIEW 
Literature surrounding the medical study of AYA oncology and the developmental 
process of AYA cancer patients has developed dynamically since first emersion in the late 
1970s. The field of nursing initiated study of psychosocial and developmental challenges of this 
population and has remained a strong and consistent voice in advocacy for this group.18-21 Early 
published works focused on how different nursing methods could aid the patient and improve 
quality of life during treatment.19 Other publications note how difficult young adult patients can 
be to treat due to disrespectful behavior and share best practices.20 In 1991 a team of nurses 
published an article identifying two areas of development that needed to be researched further: 
the impact of cancer on development during adolescence; and the various coping strategies and 
styles of the adolescent cancer patient.21  
In 1980, a team of medical doctors conducted a study of 23 patients ages 5 to 35 to 
investigate the distinctive clinic-pathology of specific carcinoma in liver found in adolescent and 
young adult patients.22 This was one of the first acknowledgements of differing biology in 
adolescent and young adult cancers. In the mid-1990s, a call for an interdisciplinary team of 
providers was made by an oncologist in Britain due to the physical, educational, and emotional 
needs of this group; increasingly, psychosocial needs of the patient were being addressed by 
medical doctors.19 A noted oncologist wrote: “In contrast to the broadly accepted view of 
adolescence as a 'time apart' somewhere between childhood and adulthood, it should be viewed 
as containing elements of both of these. Adolescents are both adults and children”.19 Treatment 
must address both the conflicts of adults and children, that psychosocial care must anticipate 
adult and pediatric needs. At this point, research in AYA oncology was limited to the fields of 
nursing, medicine, and psychology.  
AYAO continued to gain momentum around the globe. In Scotland a literature review 
was conducted by oncology nurses examining the current work in psychosocial needs.23 During 
this evaluation, the authors identified five themes of pertinent support to AYA cancer patients: 
“Parents and siblings, Psychosocial issues, School and social life, Information and support, 
Sexuality and Hopefulness”.23 During this same year, Archie Bleyer MD enters the discussion of 
AYA oncology and discusses the age range used to define this population.10 Bleyer continues to 
make a unique impact on the field. Since his early AYAO publications, Bleyer has published as 
part of an interdisciplinary team of authors and offered comprehensive evaluations and direction 
for medical and psychosocial needs. He remains a key player in discussion and promotion of 
AYAO with interdisciplinary management strategies. 
Concern surrounding patient compliance to treatment solidified in 2000 with a published 
study on adolescent and young adults with various chronic diseases.13 In this study, only 23% of 
adolescents reported full compliance with health treatment and 17% reported poor compliance, 
the rest on a spectrum in between.13 In high compliance cases, adherence was promoted by 
motivation, positivity, and support in continuing normal social activities.13 One year later, the 
same lead author published a report stating that the most powerful predictor of compliance was 
support from nursing staff.24 The field of nursing steadily increased publications on AYA cancer 
patients, and called for meaning based models of research for qualitative findings.25 
A pivotal year for AYAO was in 2006 when the National Cancer Institute (NCI) and the 
Lance Armstrong Foundation (LAF) collaborated to create the Adolescent and Young Adult 
Oncology Peer Review Group (AYAO PRG).2 A large group of contributors were chosen from 
various fields that encounter oncology patients, including public health professionals, social 
workers, pediatric and adult oncologists, nurses, pharmaceutical specialists, public 
administration specialists, and others. The creation of the PRG solidified AYAO as a specialty of 
its own within oncology. A shift in conversation surrounding AYA cancer patients and treatment 
began with this publication; research was more focused and suggestions and criticisms direct. 
Specific topics within AYAO were defined and clear measures of improvement were set. With 
expectations set and awareness increased, this marked a new wave of participation from other 
disciplines outside of oncology and psychology. Three distinct areas of concern emerged as the 
most frequent and debated topics in AYAO: clinical trial participation and availability; 
differences in biology; and psychosocial needs. 
One of the co-chairs of the psychosocial/behavioral factors committee of the PRG was 
esteemed Dr. Brad Zebrack of the School of Social Work at the University of Michigan.2,26 
Zebrack was the first resilient interdisciplinary voice in the field of AYAO and published many 
articles on information and psychosocial needs of AYA cancer patients.14,16–18,26–29 Awarded a 
doctorate of Social Work and Sociology, Masters of Social Work, and Masters of Public Health, 
Zebrack researches matters of psychosocial durability and quality of life in young cancer 
patients. His work encompasses pediatric and AYA age ranges and comments on the social and 
identity formations of young adult cancer survivors.27 
Brandon Hayes-Lattin, MD is the leading voice in biological differences between adult 
and pediatric cancers. As a co-chair of the awareness breakout group at the PRG, Hayes-Lattin 
advocated that AYA cancer patients be accepted as a distinct population with unique needs.2 
This publication also addressed the descriptive nature of published works up to that point and 
called for more evidence collection and research.2 Hayes-Lattin is an AYA cancer survivor and 
is an advocate for AYA cancer patients. He brings a personal light and lens to the study of a 
population that is plagued by exaggerated symptoms and side effects. His dedication to AYAO 
has led him to start an AYA Oncology Program at Oregon Health and Science University that 
specifically targets this population’s medical and psychosocial needs. Hayes-Lattin’s 
contributions to AYAO have lent a realistic view of the trials that these patients face when 
confronted with a chronic disease. Specifically, he has become an advocate for the study of 
differing biology between adult and AYA cancers. His work supports the claim that oncologists 
can better the lives of their patients by better understanding the specific biological functioning in 
addition to addressing the psychosocial needs of each patient. Hayes-Lattin offers person 
consultations with AYA cancer patients at Oregon Health and Science University in an effort to 
better explain their treatment and/or offer advice and resources on how to cope with other issues 
attached to a cancer diagnosis. The work of Hayes-Lattin has shaped further research for this 
group and increased awareness throughout the clinical and social services.  
The majority of authors are in agreement that increased collaboration between adult and 
pediatric oncologists is needed in addition to addressing the psychosocial needs of the 
population. Both adult and pediatric oncologists call for increased collaboration between the two 
fields to decrease the “no man’s land” many AYAs find themselves in. One example of this is 
the improvement in collaboration is the reconsideration of age restrictions for pediatric clinical 
trials.3 Many advocates concentrate all resources on improving psychosocial needs of patients, 
but the majority of oncologists weighing in on the conversation identify clinical trials as the 
primary concern for the AYA population. Distinct need for biological research and clinical trials 
remains the highest urgency found in AYAO literature as a whole due to the origin of this 
defined population which has decreased or plateaued five year survival rates.  
The route to increase biological data on this population is debated, as the cause of low 
clinical trials is a plexus of systemic barriers. Several authors attribute low clinical trial data to 
poor physician recruitment, availability of trials for patients in the AYA age range, low 
adherence rates from patients once enrolled in a trial, or a combination of these causes. Physician 
interest in initiating research on AYA cancers is still relatively low due to the recent emergence 
of the specialty; increased awareness of this population may assist in increasing attention. 
Current AYA providers face protocol and financial barriers to completing a clinical trial due to 
age restrictions and lack of grant funding.1,2,12 Trial eligibility and referral patterns to those trials 
remain convoluted and exclusive to older and younger cancer patients.1,2,10 One example is in the 
study of germ cell tumors in adolescents; male patients with testicular or extragonadal germ cell 
tumors are excluded from pediatric trials once they reach the age of 15, yet females with ovarian 
germ cell tumors may enroll in pediatric trials until the age of 21.1 Butow describes two general 
frameworks of thought surrounding adherence behaviors in AYAs: interactions between the 
patient and their medical team and the patient’s personal cognitive-motivational processes.12 
Both frameworks address adherence as a dynamic process relative to each individual patient. 
CONCLUSION 
In recognition of the body of literature surrounding AYA circumstance, an additional 
category of psychosocial and practical needs must be included in the discussion surrounding 
adherence. Many studies on adherence to cancer treatment and other chronic illnesses between 
the ages of 15 and 39 point to a distinct correlation between psychosocial needs met and 
adherence to treatment and clinical trial participation.1,3,11,12,13,23,24  Autonomy, relationships, 
education, employment, and social maturation can all affect adherence of adolescent 
patients.1,12,14,13,24 Functional needs such as transportation, childcare, employment, and insurance 
coverage are direct barriers to adherence in clinical trials and treatment.1,3,12,14,17,13,30–32 However, 
emotional and psychological needs also effect patient engagement and adherence. Increased 
stigma and anxiety surrounding the stress and physical pain of cancer treatment is often a 
deterrent for patients to interact with their medical providers and engage in any research or 
clinical trial.1–3,33 Confidence, family relationships, friendship, support from medical staff, and 
autonomy deprivation can all significantly alter the motivation and cognitive processes of the 
patient.2,14,21,24,31,33  
Lack of psychosocial support both during and after treatment increases risk of 
nonadherence. A proposed solution to the deficit of care for AYA cancer patients echoes much 
of what has already been discussed in the field: there must be a clear clinical referral pathway 
between pediatric and internal medicine; increased awareness and urgency must be conveyed to 
the public to stimulate grant funding; psychosocial needs must be addressed; benign and 
malignant specimen banking must increase; and AYA specific clinical trials must increase. But 
in addition, the manner in which AYAs are treated must be evaluated. Psychosocial needs must 
be met at the forefront of a patient’s treatment to increase adherence. Psychosocial services must 
become an integral part of AYA cancer treatment, and clinical trials must be intentionally 
designed to overcome common barriers for AYAs including practical, emotional, and social 
support. Only when the entirety of a patients needs are met can the oncology community increase 
survival rates for the population.  Utilizing a holistic approach with AYA patients is necessary to 
stimulate clinical trial participation and increase survival rates for this population. 
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